Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNZ37C)

Drug Name

N-Tridecanoic Acid Drug Info

Synonyms

TRIDECANOIC ACID; 638-53-9; n-Tridecanoic acid; Tridecylic acid; n-Tridecoic acid; NSC 25955; UNII-19936LIY2V; EINECS 211-341-1; NSC 69131; BRN 0508317; AI3-04166; CHEBI:45919; SZHOJFHSIKHZHA-UHFFFAOYSA-N; 19936LIY2V; 68002-90-4; C13:0; n-Tridecanoic acid, 97%; Tridecanoic acid, > Tridecanoic acid anion; WLN: QV12; Fatty acids, C10-16; C10-16 fatty acids; Tridecylate; Carboxylic acids, C10-16; tridecoic acid; n-Tridecanoate; n-Tridecoate; (C10-C16) Carboxylic acid; (C10-C16)Alkylcarboxylic acid; EINECS 268-105-6

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 12530
ChEBI ID: CHEBI:45919
CAS Number: CAS 638-53-9
TTD Drug ID: DMNZ37C

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Group IIA phospholipase A2 (GIIA sPLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH064	DMR1NYF	Breast cancer	2C60-2C65	Clinical trial	[2]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[3]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[3]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[1]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[4]
CACOSPONGIONOLIDE	DMIPJUS	Discovery agent	N.A.	Investigative	[5]
Elaidoylamide	DMP8VDT	Discovery agent	N.A.	Investigative	[3]
Cacospongionolide E	DM2DYAV	Discovery agent	N.A.	Investigative	[5]
CACOSPONGIONOLIDE B	DMCSXNW	Discovery agent	N.A.	Investigative	[5]
BOLINAQUINONE	DMVB6UG	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Phospholipase A2 (PLA2G1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[3]
Miltefosine	DMND304	Chronic urticaria		Approved	[7]
Clocortolone	DM9ZMQH	Exanthem		Approved	[8]
Clobetasol	DMUXP52	Rosacea	ED90.0	Approved	[9]
Diflorasone	DMI9PRJ	Exanthem		Approved	[10]
AllerB	DM78DOT	Allergy	4A80-4A85	Phase 2b	[11]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[12]
MANOALIDE	DMB4A8I	Arthritis	FA20	Phase 2	[13]
MRX-4	DMQZWYE	Allergic rhinitis	CA08.0	Phase 2	[14]
MRX-6	DMLVQKF	Contact dermatitis	EK0Z	Phase 2	[15]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Group IIA phospholipase A2 (GIIA sPLA2)	TTO8QRU	PA2GA_HUMAN	Inhibitor	[1]
Phospholipase A2 (PLA2G1B)	TT9V5JH	PA21B_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
5	A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
6	New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
7	Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.
8	Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8.
9	Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203.
10	Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11.
11	Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54.
12	Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4.
13	Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7.
14	Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008
15	A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5.